Clinical pharmacists' participation in the management of piperacillin-tazobactam and moxifloxacin-induced hematologic toxicity:pharmaceutical practice and experience
Objective This paper aims to analyze the possible causes and management strategies for pancytopenia in a patient,in order to provide support for the safe and rational use of piperacillin-tazobactam(TZP)and moxifloxacin(MFX)in clinical practice.Methods Clinical pharmacists participated in the pharmaceutical consultation and monitoring of a patient who de-veloped pancytopenia after using TZP and MFX.Considering the patient's medication history and disease progression,the possible causes of pancytopenia were analyzed through literature review,and disposal suggestions were proposed.Results Clinical pharmacists comprehensively considered the patient's medication history and disease course,and analyzed that the pancytopenia may be caused by TZP and MFX.Therefore,it was recommended to discontinue TZP and MFX,adjust the anti-infection regimen,and provide symptomatic treatment.Conclusion TZP and MFX have adverse reactions on the hema-tologic system.Clinical pharmacists should continuously strengthen their learning,play their role in clinical pharmaceutical practice,provide relevant pharmaceutical monitoring,and ensure the safe and rational use of medications for patients.
万方数据
维普
